(19)
(11) EP 2 904 103 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.03.2020 Bulletin 2020/11

(45) Mention of the grant of the patent:
22.01.2020 Bulletin 2020/04

(21) Application number: 13844080.5

(22) Date of filing: 30.09.2013
(51) International Patent Classification (IPC): 
C12N 15/867(2006.01)
A61P 1/16(2006.01)
A61K 38/45(2006.01)
A61K 35/545(2015.01)
 C12N 5/10(2006.01)
A61P 11/00(2006.01)
A61K 38/46(2006.01)
(86) International application number:
PCT/CN2013/001187
(87) International publication number:
WO 2014/053082 (10.04.2014 Gazette 2014/15)

(54)

METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELLS AND ITS APPLICATIONS

VERFAHREN ZUR HERSTELLUNG INDUZIERTER PLURIPOTENTER STAMMZELLEN UND DEREN ANWENDUNGEN

PROCÉDÉ DE PRÉPARATION DE CELLULES SOUCHES PLURIPOTENTES INDUITES ET SES APPLICATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 01.10.2012 US 201261708128 P
24.10.2012 US 201261717871 P

(43) Date of publication of application:
12.08.2015 Bulletin 2015/33

(73) Proprietor: Taipei Veterans General Hospital
Taipei City, Taiwan 11217 (TW)

(72) Inventors:
  • CHIEN, Yueh
    Taipei City 11217 Taiwan (TW)
  • CHIOU, Guang-Yuh
    Taipei City 11217 Taiwan (TW)
  • YANG, Yi-Ping
    Taipei City 11267 (TW)
  • CHIOU, Shih-Hwa
    Taipei City 11217 Taiwan (TW)

(74) Representative: Hoefer & Partner Patentanwälte mbB 
Pilgersheimer Straße 20
81543 München
81543 München (DE)


(56) References cited: : 
WO-A1-2012/116111
US-B1- 8 048 675
 CN-A- 102 653 774
US-B2- 8 058 065
   
  • MASSIMO DE FELICI: "Nuclear Reprogramming in Mouse Primordial Germ Cells: Epigenetic Contribution", STEM CELLS INTERNATIONAL, vol. 122, no. 4, 1 January 2011 (2011-01-01), pages 1235-15, XP055249427, DOI: 10.1016/j.modgep.2004.12.007
  • LOH KYLE M ET AL: "Epigenetics: Actors in the cell reprogramming drama", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 488, no. 7413, 30 August 2012 (2012-08-30), pages 599-600, XP009188497, ISSN: 1476-4687
  • OEGE, CLAUDIA A. ET AL.: 'Early-stage epigenetic modification during somatic cell eprogramming by Parpl and Tet2.' NATURE. vol. 488, 19 August 2012, pages 652 - 655, XP055248925
  • LI, HSIN-YANG ET AL.: 'Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells.' BIOMATERIALS vol. 32, 11 June 2011, pages 5994 - 6005, XP028097254
  • LAI, YI-SHIN ET AL.: 'SRY (sex determining region Y)-box2 (Sox2)/poly ADP-ribose polymerase 1 (Parpl) complexes regulate pluripotency.' PNAS. vol. 109, no. 10, 06 March 2012, pages 3772 - 3777, XP055248928
  • CHIOU, SHIH-HWA ET AL.: 'Poly(ADP-ribose) polymerase 1 regulates nuclear reprogramming and promotes iPSC generation without c-Myc.' JEM. vol. 210, no. 1, 31 December 2012, pages 85 - 98, XP055194521
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).